This company has been marked as potentially delisted and may not be actively trading. NASDAQ:OASM Oasmia Pharmaceutical AB (publ) (OASM) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Oasmia Pharmaceutical AB (publ) Stock (NASDAQ:OASM) Get OASM alerts:Sign Up Key Stats Today's Range N/A50-Day Range$1.30▼$1.6252-Week Range N/AVolumeN/AAverage Volume98,414 shsMarket Capitalization$375 thousandP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden. Read More Receive OASM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oasmia Pharmaceutical AB (publ) and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. OASM Stock News HeadlinesDouble Bond Pharmaceutical International AB (DBPHAb)October 31, 2024 | investing.comSector-Health Care & PharmaceuticalsMay 17, 2024 | newsweek.comNCrashGPT coming on Dec. 18 …Sam Altman is expected to reveal a confidential OpenAI document around 4 p.m. on Dec. 18, just weeks before a potential IPO. The disclosure could trigger a 40 trillion dollar wealth shift. Altman himself has warned that someone is going to lose a phenomenal amount of money while others gain just as much.October 24 at 1:00 AM | Weiss Ratings (Ad)BOEUF Bonesupport Holding AB (publ)April 30, 2024 | seekingalpha.comResurs Holding AB (publ) (RESURS.ST)February 7, 2024 | finance.yahoo.comQuiaPEG Pharmaceuticals Holding AB QUIAJanuary 6, 2024 | morningstar.comMNewbury Pharmaceuticals AB (NEWBRY)November 29, 2023 | investing.comLipigon Pharmaceuticals AB (LPGO)September 14, 2023 | investing.comSee More Headlines OASM Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Oasmia Pharmaceutical AB (publ) own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oasmia Pharmaceutical AB (publ) investors own include ACADIA Pharmaceuticals (ACAD), Achieve Life Sciences (ACHV), Adverum Biotechnologies (ADVM), Aethlon Medical (AEMD), Agios Pharmaceuticals (AGIO), Agile Therapeutics (AGRX) and Akebia Therapeutics (AKBA). Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:OASM CIK1607245 Webwww.oasmia.com Phone(461) 850-5440FaxN/AEmployees57Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.95 million Net Margins-8,633.64% Pretax MarginN/A Return on Equity-43.94% Return on Assets-28.92% Debt Debt-to-Equity RatioN/A Current Ratio0.80 Quick Ratio0.73 Sales & Book Value Annual Sales$220 thousand Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$0.63 per share Price / BookN/AMiscellaneous Outstanding Shares74,967,000Free FloatN/AMarket Cap$375 thousand OptionableNot Optionable Beta0.96 7 Best Space Stocks to Own in 2026The space race is growing fast, and you don’t have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important.Get This Free Report This page (NASDAQ:OASM) was last updated on 4/8/2026 by MarketBeat.com Staff. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | SponsoredWhy tech stocks are deadAI skeptics see dot-com era warning signs, and they have a point. But the real opportunity may not be in the b...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | SponsoredYou haven't downloaded this yetBill Poulos's Top 10 Stocks to Buy This Quarter report is still available free, but not for long. Every quarte...Profits Run | SponsoredSpaceX is worth trillions. This one's $14.It is not SpaceX, Tesla, Starlink, or Neuralink. But Elon's rocket company shows up in this stock's paperwork,...Behind the Markets | SponsoredTicker Revealed: Pre-IPO Access to "Next Elon Musk" CompanyWe’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billi...Banyan Hill Publishing | SponsoredAsk a 20 Year Trading Pro Your Stock Questions Live for 5Ross Givens, a market analyst with over 20 years on Wall Street, goes live every Monday at 9 AM ET to break do...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oasmia Pharmaceutical AB (publ) Please log in to your account or sign up in order to add this asset to your watchlist. Share Oasmia Pharmaceutical AB (publ) With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
